Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995463 | 0.85 | DNM1 (0.38) | ALDH1A1TSHRCHRM1L3MBTL1CHRNB2 | |
| SCHEMBL3910325 | 0.84 | MGAM (0.44) | MGAMGAASIMGAM2CA12 | |
| SCHEMBL10081285 | 0.81 | PRKCA (0.37) | GAAALDH1A1TDP1TSHRL3MBTL1 | |
| SCHEMBL24489251 | 0.81 | NAAA (0.49) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL19034578 | 0.81 | MAPT (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL10084981 | 0.80 | MEN1 (0.38) | MGAMGAASIMGAM2TDP1 | |
| SCHEMBL24368308 | 0.79 | GPR88 (0.35) | ALDH1A1CYP3A4TDP1TSHRLMNA | |
| SCHEMBL25935745 | 0.78 | GAA (0.43) | MGAMGAASIMGAM2CA12 | |
| SCHEMBL19242303 | 0.77 | CYP3A4 (0.45) | CA2ALDH1A1CYP3A4TDP1TSHR | |
| SCHEMBL10081268 | 0.77 | LMNA (0.36) | TDP1TSHRLMNACYP2D6CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218722-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3860561-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-2788316-B1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9687448-B2 | Nucleic acid lipid particle formulations | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2575764-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2016-01-14 | — | — | US | disclosed |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | BANK OF AMERICA, N.A. | 2015-10-29 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9012498-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | BANK OF AMERICA, N.A. | 2015-01-01 | — | — | US | disclosed |
| WO-2014089239-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086322-A1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2011153493-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | LIPA, CETP, APOB | MGAM 2476/4885GAA 307/4885SI 547/4885 |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | MGAM 2499/4885GAA 311/4885SI 412/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | MGAM 2416/4885GAA 253/4885SI 603/4885 |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | MGAM 2416/4885GAA 253/4885SI 603/4885 |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | MGAM 3752/4885GAA 617/4885SI 2193/4885 |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, NPC1L1, CETP | MGAM 3778/4885GAA 580/4885SI 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.